



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/993,687	11/14/2001	David Botstein	P2730P1C11	4943
35489	7590	09/27/2006	EXAMINER	
HELLER EHRMAN LLP 275 MIDDLEFIELD ROAD MENLO PARK, CA 94025-3506			KEMMERER, ELIZABETH	
			ART UNIT	PAPER NUMBER

1646

DATE MAILED: 09/27/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/993,687	BOTSTEIN ET AL.	
	Examiner	Art Unit	
	Elizabeth C. Kemmerer, Ph.D.	1646	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 27 July 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 119-126 and 129-131 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 119-126 and 129-131 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>6/29/06</u> | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Continued Examination

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submissions filed on 29 June 2006 and 27 July 2006 have been entered.

Status of Application, Amendments and/or Claims

Claims 119-126 and 129-131 are under consideration in the instant application. Applicant's remarks submitted 29 June 2006 have been entered into the record. The second declaration by Dr. Polakis (received 29 June 2006) has been entered into the record, and is addressed below.

Information Disclosure Statement

The information disclosure statement submitted on 29 June 2006 has been fully considered.

Claim Rejections - 35 USC § 101 and 35 USC § 112, first paragraph

Claims 119-126 and 129-131 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a credible, specific and substantial asserted

Art Unit: 1646

utility or a well established utility. Novel biological molecules lack well established utility and must undergo extensive experimentation to determine their utility. The basis for this rejection is of record.

The claims are directed to isolated polypeptides comprising an amino acid sequence at least 80% identical to the amino acid sequence of SEQ ID NO: 194 with or without its signal peptide, or the amino acid sequence of the full-length coding sequence of the cDNA deposited under ATCC accession number 209977, wherein the nucleic acid encoding said polypeptide is amplified in colon tumors. It is noted that the phrase "wherein the nucleic acid encoding said polypeptide is amplified in colon tumors" is not an activity limitation for the claimed polypeptides; rather, it is a characteristic of a nucleic acid. In other words, the claims do not require that the claimed polypeptides be overexpressed in any tumor, or have any biological activity. Claims are also presented to chimeric proteins comprising the aforementioned polypeptides. The specification discloses the polypeptide of SEQ ID NO: 194, also known as PRO1009. Applicants have gone on record as relying upon the gene amplification assay as providing utility and enablement for the claimed polypeptides. See Appeal Brief (received 07 February 2006), p. 4, beginning of arguments. (It is noted that the specification asserts several other utilities for the claimed polypeptides, all of which have been found to be non-specific and/or insubstantial. For discussion of these utilities, see Office Action mailed 19 March 2004. However, these asserted utilities will not be re-addressed here due to Applicants' indication that they are relying upon the gene amplification assay for utility and enablement.)

At pages 539-555, Example 170 discloses a gene amplification assay in which genomic DNA encoding PRO1009 had a ΔC_t value of at least 1.0 for twelve out of seventeen colon tumor samples. Example 170 asserts that gene amplification is associated with overexpression of the gene product (i.e., the polypeptide), indicating that the polypeptides are useful targets for therapeutic intervention in cancer and diagnostic determination of the presence of cancer (p. 539, lines 21-24). At page 548, ΔC_t is defined as the threshold PCR cycle, or the cycle at which the reporter signal accumulates above the background level of fluorescence. The specification further indicates that ΔC_t is used as "a quantitative measurement of the relative number of starting copies of a particular target sequence in a nucleic acid sample when comparing cancer DNA results to normal human DNA results." It is noted that at page 548, it is stated that samples are used if their values are within 1 Ct of the 'normal standard'. It is further noted that the ΔC_t values at pages 550-554 are expressed (a) with values to one one-hundredth of a unit (e.g. 1.29), and (b) that very few values were obtained that were at least 2.

While these data support utility and enablement of PRO1009 *genomic DNA* for use in colon tumor diagnosis, the data have no bearing on the utility of the claimed PRO1009 *polypeptides and polypeptide variants*. In order for PRO1009 polypeptides to be overexpressed in tumors, amplified genomic DNA would have to correlate with increased mRNA levels, which in turn would have to correlate with increased polypeptide levels. No data regarding PRO1009 mRNA or PRO1009 polypeptide levels in colon tumors have been brought forth on the record. The art discloses that a

Art Unit: 1646

correlation between genomic DNA levels and mRNA levels cannot be presumed, nor can any correlation between mRNA levels and polypeptide levels. Regarding the correlation between genomic DNA amplification and increased mRNA expression, see Pennica et al. (1998, PNAS USA 95:14717-14722), who disclose that:

“An analysis of *WISP-1* gene amplification and expression in human colon tumors showed a correlation between DNA amplification and overexpression, whereas overexpression of *WISP-3* RNA was seen in the absence of DNA amplification. In contrast, *WISP-2* DNA was amplified in the colon tumors, but its mRNA expression was significantly reduced in the majority of tumors compared with the expression in normal colonic mucosa from the same patient.”

See p. 14722, second paragraph of left column; pp. 14720-14721, “Amplification and Aberrant Expression of *WISPs* in Human Colon Tumors.” See also Konopka et al. (Proc. Natl. Acad. Sci. (1986) 83:4049-4052), who state that “Protein expression is not related to amplification of the *abl* gene but to variation in the level of *bcr-abl* mRNA produced from a single Ph1 template” (see abstract).

Moreover, even if increased mRNA levels could be established for PRO1009, it does not follow that PRO1009 polypeptide levels would also be amplified. Chen et al. (2002, Molecular and Cellular Proteomics 1:304-313) compared mRNA and protein expression for a cohort of genes in the same lung adenocarcinomas. Only 17% of 165 protein spots or 21% of the genes had a significant correlation between protein and mRNA expression levels. Chen et al. clearly state that “the use of mRNA expression patterns by themselves, however, is insufficient for understanding the expression of protein products” (p. 304) and “it is not possible to predict overall protein expression levels based on average mRNA abundance in lung cancer samples” (pp. 311-312).

Art Unit: 1646

Also, Hu et al. (2003, *Journal of Proteome Research* 2:405-412) analyzed 2286 genes that showed a greater than 1-fold difference in mean mRNA expression level between breast cancer samples and normal samples in a microarray (p. 408, middle of right column). Hu et al. discovered that, for genes displaying mRNA changes of 5-fold or less in tumors compared to normal, there was no evidence of a correlation between altered mRNA expression and a known role in the disease. However, among genes with a 10-fold or more change in mRNA expression level, there was a strong and significant correlation between mRNA expression level and a published role in the disease (see discussion section). One of the authors of this paper, Dr. LaBaer, made an even stronger statement that reports of mRNA or protein changes of as little as two-fold are not uncommon, and although changes of this magnitude may turn out to be important, **most** are attributable to disease-independent differences between the samples (emphasis added; 2003, *Nature Biotechnology* 21:976-977).

The art also shows that transcript levels do not correlate with polypeptide levels in normal tissues. See Haynes et al. (1998, *Electrophoresis* 19:1862-1871), who studied more than 80 polypeptides relatively homogeneous in half-life and expression level, and found no strong correlation between polypeptide and transcript level. For some genes, equivalent mRNA levels translated into polypeptide abundances which varied more than 50-fold. Haynes et al. concluded that the polypeptide levels cannot be accurately predicted from the level of the corresponding mRNA transcript (p. 1863, second paragraph, and Figure 1). Gygi et al. (1999, *Mol. Cell. Biol.* 19:1720-1730) conducted a similar study with over 150 polypeptides. They concluded that

Art Unit: 1646

“the correlation between mRNA and protein levels was insufficient to predict protein expression levels from quantitative mRNA data. Indeed, for some genes, while the mRNA levels were of the same value the protein levels varied by more than 20-fold. Conversely, invariant steady-state levels of certain proteins were observed with respective mRNA transcript levels that varied by as much as 30-fold. Our results clearly delineate the technical boundaries of current approaches for quantitative analysis of protein expression and reveal that simple deduction from mRNA transcript analysis is insufficient”

(See Abstract). Lian et al. (2001, Blood 98:513-524) show a similar lack of correlation in mammalian (mouse) cells (see p. 514, top of left column: “The results suggest a poor correlation between mRNA expression and protein abundance, indicating that it may be difficult to extrapolate directly from individual mRNA changes to corresponding ones in protein levels.”). See also Fessler et al. (2002, J. Biol. Chem. 277:31291-31302) who found a “[p]oor concordance between mRNA transcript and protein expression changes” in human cells (p. 31291, abstract).

Therefore, data pertaining to PRO1009 genomic DNA do not indicate anything significant regarding the claimed PRO1009 polypeptides. The data do not support the specification's assertion that PRO1009 polypeptides can be used as a cancer diagnostic agent. Significant further research would have been required of the skilled artisan to reasonably confirm that the claimed PRO1009 polypeptides or variants thereof are overexpressed in any cancer to the extent that they could be used as cancer diagnostic agents, and thus the asserted utility is not substantial. In the absence of information regarding whether or not PRO1009 polypeptide levels are also different between specific cancerous and normal tissues, the proposed use of the PRO1009

Art Unit: 1646

polypeptides as diagnostic markers and therapeutic targets are simply starting points for further research and investigation into potential practical uses of the polypeptides.

See *Brenner v. Manson*, 148 U.S.P.Q. 689 (Sup. Ct., 1966), wherein the court held that:

"The basic quid pro quo contemplated by the Constitution and the Congress for granting a patent monopoly is the benefit derived by the public from an invention with substantial utility", "[u]nless and until a process is refined and developed to this point-where specific benefit exists in currently available form-there is insufficient justification for permitting an applicant to engross what may prove to be a broad field", and "a patent is not a hunting license", "[i]t is not a reward for the search, but compensation for its successful conclusion."

Claims 119-126 and 129-131 are also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a credible, specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention. This lack of enablement rejection applies to the PRO1009 polypeptide of SEQ ID NO: 194 as well as the claimed variants thereof.

Applicants' arguments (29 June 2006), as they pertain to the rejections have been fully considered but are not deemed to be persuasive for the following reasons.

Applicants incorporate the arguments made in the Appeal Brief (received 07 February 2006) and the Rely Brief into their arguments. Applicants are advised that no Reply Brief has been received for this application. Furthermore, the response to the

arguments made in the Appeal Brief can be found in the Examiner's Answer mailed 02 May 2006.

Applicants refer to the second declaration of Dr. Polakis (Polakis II), submitted with the response (filed 29 June 2006). Applicants argue that this declaration provides the facts, set forth in a table (Exhibit B), for independent evaluation by the Examiner. The second Polakis declaration under 37 CFR § 1.132 filed 29 June 2006 is insufficient to overcome the rejection of claims 119-126 and 129-131 based upon 25 U.S.C. §§ 101 and 112, first paragraph, for the following reasons. Specifically, data for PRO1009 does not appear in the table (Exhibit B). Furthermore, it is not clear how the clones appearing in the table compare to PRO1009, or if the results presented in the table were determined by the same methodology as presented in the instant specification. For example, were the genes corresponding to the mRNAs tested amplified? How highly elevated were the mRNAs in Exhibit B that purportedly correlate with increased protein levels, 2-fold, 5-fold, 10-fold? How many samples were used? By what means was the level of mRNA expression determined, e.g., microarray, Northern blot, quantitative PCR? Was the "universal normal control" used or were matched tissue controls used? The declaration only states that levels of mRNA and protein in tumor tissue were compared to normal tissue.

In the remarks received 29 June 2006, Applicants have submitted teachings from Alberts, B. (Molecular Biology of the Cell (3rd ed 1994 and 4th ed 2002)) and Lewin, B. (Genes VI 1997) to support the statements of Dr. Polakis (Polakis I and Polakis II declarations; addressed below). Applicants also cite numerous references to

Art Unit: 1646

emphasize that those of skill in the art would not be focusing on differences in gene expression between cancer cells and normal cells if there were no correlation between gene expression and protein expression (such as Zhigang et al., Meric et al. Orntoft et al., Wang et al., Munaut et al., etc.). Applicants assert that changes in mRNA level generally lead to corresponding changes in the level of expressed protein. Applicants also contend that the references and the Polakis declarations establish that the accepted understanding in the art is that there is a reasonable correlation between changes in gene expression and the level of the encoded protein. Applicants' arguments have been fully considered but are not found to be persuasive. While the Examiner acknowledges the teachings of Alberts and Lewin, which disclose that initiation of transcription is a common point for a cell to regulate the gene expression, it is not the only means of regulating gene expression. For example, Alberts also teaches that there are a number of other controls that can act later in the pathway from RNA to protein to modulate the amount of protein that is made, including translational control mechanisms and mRNA degradation control mechanisms (see Alberts 3rd ed., bottom of pg 453). Meric et al. states the following:

"The fundamental principle of molecular therapeutics in cancer is to exploit the differences in gene expression between cancer cells and normal cells. [M]ost efforts have concentrated on identifying differences in gene expression at the level of mRNA, which can be attributable to either DNA amplification or to differences in transcription."

However, Meric et al. also goes on to state that gene expression is quite complicated, and is also regulated at the level of mRNA stability, mRNA translation, and protein stability (see page 971, Introduction). Meric et al. also teaches that there are a number

of translation alterations encountered in cancer, including variations in the mRNA sequence as a result of mutations, alternate splicing and transcription start sites, alternate polyadenylation sites, and alterations in the components of the translation machinery (see pages 973-974). Celis et al. (200, FEBS Lett. 480:2-16) also teach that “[g]enes may be present, they may be mutated, but they are not necessarily transcribed. Some messengers are transcribed but not translated, and the number of mRNA copies does not necessarily reflect the number of functional protein molecules” (p. 6, col. 2).

Furthermore, with the exception of Futcher et al., all of Applicant’s newly cited references are directed to the analysis of single genes, or a small group of genes, and therefore do not demonstrate trends found across proteins in general. The studies cited by Applicant that examine the expression of specific genes or small numbers of genes are not found persuasive in view of comprehensive studies where significantly larger numbers of transcripts and proteins were examined and more accurately describe general trends, specifically, Haynes et al. (80 proteins examined) and Chen et al. (165 proteins examined) (cited previously by Examiner) and Nagaraja et al. (2006, *Oncogene* 25:2328-2338), Waghray et al. (2001, *Proteomics* 1:1327-1338) and Sagynaliev et al. (2005, *Proteomics* 5:3066-3078) (described below).

With regard to the Orntoft reference, Applicants submit that Orntoft examined 40 well-resolved abundant proteins, and found significant correlation between mRNA and protein alterations (including both increases and decreases) for each gene, except one. Applicants’ arguments with respect to Orntoft have been fully considered but are not found to be persuasive. Orntoft et al. appear to have looked at increased DNA content

over large regions of chromosomes and compare that to mRNA and polypeptide levels from the chromosomal region. Their approach to investigating gene copy number was termed CGH. Orntoft et al. do not appear to look at gene amplification, mRNA levels and polypeptide levels from a single gene at a time. Orntoft et al. concentrated on *regions* of chromosomes with strong gains of chromosomal material containing clusters of genes (p. 40). This analysis was not done for PRO1009 in the instant specification. That is, it is not clear whether or not PRO1009 is in a gene cluster in a region of a chromosome that is highly amplified. Therefore, the relevance, if any of Orntoft et al. is not clear.

Applicants also assert that Futcher et al. (1999) conducted a study of mRNA and protein expression in yeast and report a good correlation between protein abundance, mRNA abundance, and codon bias. Applicants' arguments have been fully considered but are not found to be persuasive. Futcher et al conclude that "[t]his validates the use of mRNA abundance as a rough predictor of protein abundance, at least for relatively abundant proteins [emphasis added]" (p. 7368, col. 1). Futcher et al. also admit that Gygi et al. performed a similar study and generated similar data, but reached a different conclusion. Futcher et al. indicate that "Gygi et al. feel that mRNA abundance is a poor predictor of protein abundance" (p. 7367, col. 1, 1st full paragraph).

The Examiner maintains the previous argument that mRNA levels are not necessarily predictive of protein levels, and in response to Applicants' arguments, maintains that this is true even when there is a change in the mRNA level. Comprehensive studies where significantly large numbers of transcripts and proteins

were examined report that increases in mRNA and protein samples are not correlated. Nagaraja et al. (2006, *Oncogene*, 25:2328-2338) characterized comprehensive transcript and proteomic profiles of cell lines corresponding to normal breast (MCF10A), noninvasive breast cancer (MCF7) and invasive breast cancer (MDS-MB-231) and report that "the proteomic profiles indicated altered abundance of fewer proteins as compared to transcript profiles" (see abstract), and "the comparison of transcript profiles with proteomic profiles demonstrated that altered proteins were not always represented in the microarray designated profiles and vice versa" (see p. 2329, first column). Nagaraja et al. further report that, "a comparative analysis of transcripts and proteins to establish a relationship between transcript changes and protein levels has not yet become routine" (see p. 2328, second column). Lastly, Nagaraja et al. report that, "as dictated by post-transcriptional regulation, protein profiles showed far fewer changes as compared to transcript profiles" (see p. 2335, first column).

Similar results were reported by Waghray et al. (2001, *Proteomics*, 1:1327-1338). Waghray et al. analyzed gene expression changes induced by dihydrotestosterone (DHT) in the androgen responsive cancer line LNCaP, at both RNA and protein levels (see abstract). In this study, Waghray et al identified transcripts from 16750 genes and found 351 genes were significantly altered by DHT treatment and the RNA level, and identified 1031 proteins and found 44 protein spots that changed in intensity (either increased or decreased). Out of the 44 protein spots that changed in intensity, Waghray et al. reports that, "remarkably, for most of the proteins identified, there was no appreciable concordant change at the RNA level" (see p. 1333-1334, Table 4).

Art Unit: 1646

Waghray et al. clearly state that, "The change in intensity for most of the affected proteins identified could not be predicted based on the level of the corresponding RNA" (see abstract).

In a review of gene expression in colorectal cancer (CRC), Sagynaliev et al. (2005, *Proteomics*, 5:3066-3078) report that "it is also difficult to reproduce transcriptomics results with proteomics tools. Out of 982 genes found to be differentially expressed in human CRC by genome-wide transcriptomics technologies (Table 6a), only 177 (18%) have been confirmed using proteomics technologies" (see p. 3068). In summary, it is clear that Nagaraja et al., Waghray et al. and Sagynaliev et al. support the Examiner's position that changes in mRNA expression frequently do not result in changes in protein expression. It is also noted that the specification of the instant application does not teach a change in mRNA level of PRO1009. There are no teachings in the specification as to the differential expression of PRO1009 mRNA in the progression of colon cancer or in response to different treatments of hormones (for example). Therefore, the Examiner maintains that Applicants' measurement of an increase of PRO1009 genomic DNA does not provide a specific and substantial utility for the encoded protein.

The state of the art, as evidenced through textbooks and review papers, clearly establishes that polypeptide levels cannot be accurately predicted from mRNA levels. Lilley et al. (2003, "Proteomics" *Molecular Biology in Cellular Pathology*, England: John Wiley & Sons, p. 351) teach that "DNA chips (mRNA profiling studies) can contribute to the study of gene expression in response to a particular biological perturbation.

Art Unit: 1646

However, the extrapolation that changes in transcript level will also result in corresponding changes in protein amount or activity cannot always be made.”

Wildsmith et al. also disclose that the gene expression data obtained from a microarray may differ from protein expression data (“Gene Expression Analysis Using Microarrays” Molecular Biology in Cellular Pathology, (2003) England: John Wiley & Sons, pp. 269-286, especially p. 283). King et al. (2001, J. American Medical Assoc. 286:2280-2288) disclose that “it has been established that mRNA levels do not necessarily correlate with protein levels” (p. 2287, 2nd full paragraph). King et al. state that it has been demonstrated that correlation between mRNA and protein abundance is less than 0.5 and that “mRNA expression studies should be accompanied by analyses at the protein level” (p. 2287, bottom of col. 1 through the top of col. 2; see also Bork et al., 2000, Genome Res. 398-400, especially p. 398, bottom of col. 3). Haynes et al. teach that “[p]rotein expression levels are not predictable from the mRNA expression levels” (p. 1863, top of left column) and “only the direct analysis of mature protein products can reveal their correct identities, their relevant state of modification and/or association and their amounts” (p. 1870, under concluding remarks). Madoz-Gurpide et al. (2003, Adv. Exp. Med. Biol. 532:51-58) disclose that “[f]or most of the published studies it is unclear how well RNA levels reported correlate with protein levels” (p. 53, 1st full paragraph). However, the specification of the instant application has only disclosed that the PRO1009 genomic DNA is amplified in some colon tumor tissue samples. The specification suggests but does not show that the PRO1009 mRNA or polypeptide has been overexpressed in the colon tumor samples tested. Given the asserted increase in

Art Unit: 1646

PRO1009 expression, and the evidence provided by the current literature, it is clear that one skilled in the art would *not* assume that an increase in mRNA expression would correlate with significantly increased polypeptide levels. Further research needs to be done to determine whether the reported increase in PRO1009 genomic DNA supports a role for the encoded polypeptide in the cancerous tissue; such a role has not been established by the instant disclosure. Such further research requirements make it clear that the asserted utility is not yet in currently available form, i.e., it is not substantial. This further experimentation is part of the act of invention and until it has been undertaken, Applicants' claimed invention is incomplete. As discussed in *Brenner v. Manson*, (1966, 383 U.S. 519, 148 USPQ 689), the court held that:

"The basic quid pro quo contemplated by the Constitution and the Congress for granting a patent monopoly is the benefit derived by the public from an invention with substantial utility", "[u]nless and until a process is refined and developed to this point-where specific benefit exists in currently available form-there is insufficient justification for permitting an applicant to engross what may prove to be a broad field", and, "a patent is not a hunting license", "[i]t is not a reward for the search, but compensation for its successful conclusion."

Accordingly, the specification's assertions that the PRO1009 polypeptides have utility in the fields of cancer diagnostics is not substantial. Thus, consideration of the preponderance of the totality of the evidence indicates that the rejection under 35 U.S.C. § 101 should be maintained.

Applicants argue that the rejection under 35 U.S.C. § 112, first paragraph, regarding enablement, should be withdrawn for reasons of record. This has been fully considered but is not found to be persuasive for reasons of record.

Claims 119-123, 130 and 131 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims are drawn to polypeptides having at least 80%, 85%, 90%, 95% or 99% sequence identity with SEQ ID NO: 194, wherein said polypeptides are encoded by nucleic acids that are amplified in colon tumors. It is noted that the phrase "wherein the nucleic acid encoding said polypeptide is amplified in colon tumors" is not an activity limitation for the claimed polypeptides; rather, it is a characteristic of a nucleic acid. In other words, the claims do not require that the claimed polypeptides be overexpressed in any tumor, or have any biological activity. Thus, the claims do not require that the *polypeptide* possess any particular biological activity, nor any particular conserved structure, or other disclosed distinguishing feature. The claims are drawn to a genus of polypeptides that is defined only by sequence identity.

To provide evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation, methods of making the claimed product, or any combination thereof. In this case, the only factor present in the claim is a partial structure in the form of a recitation of percent identity.

There is not even identification of any particular portion of the structure that must be conserved, or any activity limitations. Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus.

Vas-Cath Inc. v. Mahurkar, 19USPQ2d 1111, clearly states that “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of *the invention*. The invention is, for purposes of the ‘written description’ inquiry, *whatever is now claimed*.” (See page 1117.) The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.” (See *Vas-Cath* at page 1116). As discussed above, the skilled artisan cannot envision the detailed chemical structure of the encompassed genus of polypeptides, and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it. The compound itself is required. See *Fiers v. Revel*, 25 USPQ2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016.

One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481 at 1483. In *Fiddes*, claims directed to mammalian FGF’s were found to be unpatentable due to lack of written description for that broad class. The specification provided only the bovine sequence.

Therefore, only isolated polypeptides comprising the amino acid sequence set forth in SEQ ID NO: 194, but not the full breadth of the claim meets the written description provision of 35 U.S.C. §112, first paragraph. *Vas-Cath* makes clear that the written description provision of 35 U.S.C. §112 is severable from its enablement provision (see page 1115).

Applicants argue (p. 15, amendment received 29 June 2006) that the rejection under 35 U.S.C. § 112, first paragraph, regarding written description, should be withdrawn for reasons of record. This has been fully considered but is not found to be persuasive for reasons of record.

Conclusion

No claims are allowable.

This is a continuation of applicant's earlier Application No. 09/993,687. All claims are drawn to the same invention claimed in the earlier application and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the earlier application. Accordingly, THIS ACTION IS MADE FINAL even though it is a first action in this case. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not

Art Unit: 1646

mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no, however, event will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Applicant is advised that the instant rejection was made final because the same claims were maintained as rejected on the same grounds that have been of record. However, new references have been cited as evidence supporting the rejections of record. Applicant may submit counter-evidence in response to this office action, which will appropriately be entered after final. Alternatively, Applicant may wish to submit an Appeal Brief in response to this office action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth C. Kemmerer, Ph.D. whose telephone number is (571) 272-0874. The examiner can normally be reached on Monday through Thursday, 7:00 a.m. to 5:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol, Ph.D. can be reached on (571) 272-0835. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

ECK

Elizabeth C. Kemmerer

ELIZABETH KEMMERER
PRIMARY EXAMINER